Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M89,477Revenue $M35,367Net Margin (%)41.4Altman Z-Score2.0
Enterprise Value $M109,606EPS $6.0Operating Margin %46.9Piotroski F-Score7
P/E(ttm)6.7Beneish M-Score-1.9Pre-tax Margin (%)47.8Higher ROA y-yY
Price/Book8.410-y EBITDA Growth Rate %0.5Quick Ratio1.0Cash flow > EarningsN
Price/Sales2.85-y EBITDA Growth Rate %-5.1Current Ratio1.3Lower Leverage y-yY
Price/Free Cash Flow28.1y-y EBITDA Growth Rate %65.5ROA % (ttm)20.9Higher Current Ratio y-yY
Dividend Yield %6.0PEG--ROE % (ttm)163Less Shares Outstanding y-yY
Payout Ratio %40.0Shares Outstanding M2,171ROIC % (ttm)52.5Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKDodge & Cox 2015-06-30 Reduce-0.47%$41.65 - $48.23
($45.06)
$ 41.21-9%Reduce 46.76%12,476,998
GSKCharles Brandes 2015-06-30 Add0.23%$41.65 - $48.23
($45.06)
$ 41.21-9%Add 11.20%4,313,622
GSKHOTCHKIS & WILEY 2015-06-30 Reduce-0.11%$41.65 - $48.23
($45.06)
$ 41.21-9%Reduce 5.59%11,615,471
GSKJohn Rogers 2015-06-30 Add0.08%$41.65 - $48.23
($45.06)
$ 41.21-9%Add 16.22%1,214,427
GSKKen Fisher 2015-06-30 Add0.06%$41.65 - $48.23
($45.06)
$ 41.21-9%Add 7.22%11,533,371
GSKNWQ Managers 2015-06-30 Add0.03%$41.65 - $48.23
($45.06)
$ 41.21-9%Add 11.86%510,500
GSKTweedy Browne 2015-06-30 Reduce$41.65 - $48.23
($45.06)
$ 41.21-9%Reduce 2.33%128,285
GSKJoel Greenblatt 2015-06-30 Reduce$41.65 - $48.23
($45.06)
$ 41.21-9%Reduce 4.09%80,157
GSKJames Barrow 2015-06-30 Reduce$41.65 - $48.23
($45.06)
$ 41.21-9%Reduce 6.87%252,300
GSKCharles Brandes 2015-03-31 Add0.38%$41.68 - $48.81
($45.86)
$ 41.21-10%Add 18.20%3,879,073
GSKNWQ Managers 2015-03-31 Add0.14%$41.68 - $48.81
($45.86)
$ 41.21-10%Add 123.03%456,380
GSKKahn Brothers 2015-03-31 Add0.06%$41.68 - $48.81
($45.86)
$ 41.21-10%Add 14.12%58,200
GSKDodge & Cox 2015-03-31 Reduce-0.02%$41.68 - $48.81
($45.86)
$ 41.21-10%Reduce 2.18%23,436,551
GSKHOTCHKIS & WILEY 2015-03-31 Add0.01%$41.68 - $48.81
($45.86)
$ 41.21-10%Add 0.73%12,302,975
GSKJoel Greenblatt 2015-03-31 Add$41.68 - $48.81
($45.86)
$ 41.21-10%Add 0.41%83,578
GSKTweedy Browne 2015-03-31 Reduce$41.68 - $48.81
($45.86)
$ 41.21-10%Reduce 2.19%131,346
GSKKen Fisher 2015-03-31 Reduce$41.68 - $48.81
($45.86)
$ 41.21-10%Reduce 0.07%10,757,080
GSKDodge & Cox 2014-12-31 Reduce-0.64%$41.3 - $47.14
($44.76)
$ 41.21-8%Reduce 37.91%23,959,301
GSKHOTCHKIS & WILEY 2014-12-31 Add0.21%$41.3 - $47.14
($44.76)
$ 41.21-8%Add 13.04%12,213,885
GSKDavid Dreman 2014-12-31 Sold Out -0.01%$41.3 - $47.14
($44.77)
$ 41.21-8%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner 2015-02-23Sell503,150$2283.95view
GLAXOSMITHKLINE PLC10% Owner 2014-12-18Sell50,000$21.1491.44view
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29665.03view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12237.25view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14189.07view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12237.25view

Press Releases about GSK :

Quarterly/Annual Reports about GSK:

    News about GSK:

    Articles On GuruFocus.com
    Dodge & Cox Acquires Stake in Priceline Aug 21 2015 
    AptarGroup: The Leader in Dispensing Innovation Aug 21 2015 
    GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With Asthma Aug 06 2015 
    It’s Not Too Late To Buy Gilead Sciences Jul 17 2015 
    Tweedy Browne Global Value Adds to Eight Stakes in Portfolio Jul 14 2015 
    JW1 Jun 29 2015 
    JW1 Jun 28 2015 
    JW1 Jun 28 2015 
    JW1 Jun 28 2015 
    Weekly 3-Year Low Highlights: GSK, TRP, NOV, CHK Jun 15 2015 

    More From Other Websites
    GSK announces NEJM publication of Phase 3b/4 study of ambrisentan and tadalafil as first-line... Aug 26 2015
    Glaxo in $1 Billion Ofatumumab Deal With Novartis Aug 26 2015
    Head To Head: Barclays plc vs GlaxoSmithKline plc Aug 26 2015
    Novartis could pay more than $1B for GlaxoSmithKline MS drug Aug 21 2015
    Novartis could pay more than $1B for GlaxoSmithKline MS drug Aug 21 2015
    Pharmaceutical co. investing $2M in Memphis manufacturing facility previously for sale Aug 21 2015
    GSK sells cancer and multiple sclerosis drug to Novartis in $1bn deal Aug 21 2015
    GSK to divest ofatumumab for auto-immune indications to Novartis for up to $1 billion plus royalties Aug 21 2015
    Should You Invest In 6%+ Yielders Anglo American plc, HSBC Holdings plc, Ashmore Group plc And... Aug 19 2015
    Should You Invest In 6%+ Yielders Anglo American plc, HSBC Holdings plc, Ashmore Group plc And... Aug 19 2015
    A GSK layoff helps launch a new RTP drug developer Aug 18 2015
    GlaxoSmithKline reopens plant where Legionnaires' found Aug 17 2015
    GlaxoSmithKline reopens plant where Legionnaires' found Aug 17 2015
    GlaxoSmithKline to reopen plant where Legionnaires' found Aug 14 2015
    GlaxoSmithKline to reopen plant where Legionnaires' found Aug 14 2015
    Glaxo: Meds from plant with Legionnaires' bacteria are safe Aug 13 2015
    Glaxo: Meds from plant with Legionnaires' bacteria are safe Aug 13 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK